On November 18th the Copenhagen-based pharma giant put out word that it is buying Dicerna $DRNA — an RNAi pioneer that has had its up and downs over the years — for $3.3 billion. Novo is paying $38.25 a share — an 80% premium. That first effort in their alliance was targeted at cardiometabolics, a top priority now as Novo moves past their big R&D campaign for semaglutide and looks to put new drugs in the pipeline. The collaboration overall was exploring more than 30 liver cell targets “with the potential to deliver multiple clinical candidates for disorders including chronic liver disease, non-alcoholic steatohepatitis, type 2 diabetes, obesity and rare diseases. ”
For further information, see Endpoint News (https://endpts.com/novo-nordisk-swallows-dicerna-and-its-rnai-pipeline-in-3-3b-buyout/)
